Immunother to team up with Indian Biotech company to enhance Biotherapeutics
08/26/2020

Immunother today announced that it is joining forces with an Indian Biotech company to promote biopharmaceutical research.

Online PR News – 26-August-2020 – SHENZHEN – Immunother and the Indian institution will sign a contract under which Immunother is contributing funds to support researchers at the institute to establish the best global practices for identifying biopharmaceuticals. The research conducted by Immunother examines and reports on the quality of biotherapeutic products for the Indian market.

Immunother will be contributing funds as a part of its corporate social responsibility initiative, with the goal of enhancing the quality and safety of biotherapeutics.

Immunother’s Chairman & Chief Scientist, Mr. Geoffrey Marcus spoke about Immunother’s history of innovation, focus on research and vision for the future. He said “We are extremely happy to be laying foundations in india. Our broad range of technologies will further boost our efforts for Biopharmaceutical Technology. This mutually constructive and productive partnership will hopefully lead to promising results for the entire biotherapeutics ecosystem.”

Immunother’s Chairman & Chief Scientist, Mr. Geoffrey Marcus also added “We are excited to embark on this initiative with the country’s brightest minds engaged in research and technology. The new partnership of understanding that we have signed will further strengthen our relationship and will enhance the ability to do cutting-edge research, which can be used to improve the quality of life for the community at large, through the application of new innovations.”

About Us - Immunother

Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.

Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.